Rate control is a better initial treatment for patients with atrial fibrillation and heart failure: Rhythm control vs. rate control: Which is better in the management of atrial fibrillation? (Rate-side)

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 970-978

  Chinushi, Masaomi ^a   Iijima, Kenichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Amiodarone; Atrial fibrillation; Catheter ablation; Rate control therapy; Rhythm control therapy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DOFETILIDE; DRONEDARONE; ISOPRENALINE; MAGNESIUM SULFATE; PLACEBO; POTASSIUM; PROPAFENONE; SOTALOL;

ARTICLE; CARDIOVERSION; CATHETER ABLATION; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; QT PROLONGATION; RECURRENT DISEASE; TORSADE DES POINTES; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE;

EID: 79953666026     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0080     Document Type: Article

References (57)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 1994; 271: 840-844.
2. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm 2007; 4: S61-S64.
3. Ohtani K, Yutani C, Nagata S, Koretsune Y, Hori M, Kamada T. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 1995; 25: 1162-1169.
4. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med 1988; 85: 242-244.
5. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: Evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106: 284-291.
6. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287: 628-640.
7. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
8. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al; for RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373.
9. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al; for Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
10. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al; for STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
11. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000; 356: 1789-1794.
12. Falk RH. Is rate control or rhythm control preferable in patients with atrial fibrillation? Rate control is preferable to rhythm control in the majority of patients with atrial fibrillation. Circulation 2005; 111: 3141-3150.
13. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al; for J-RHYTHM Investigators. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
14. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
15. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527-532.
16. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
17. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
18. Japanese Circulation Society. Guidelines for Treatment of Chronic Heart Failure (JCS 2010) http://www.j-circ.or.jp/guideline/pdf/ JCS2010_matsuzaki_h.pdf (January 21, 2011).
19. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al; for Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
20. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; for Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
21. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al; for Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
22. Chouabe C, Drici MD, Romey G, Barhanin J. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie 2000; 55: 195-202.
23. Berger F, Borchard U, Hafner D. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 638-646.
24. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141.
25. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
26. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al; for J-BAF Investigators. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: A multicenter, randomized, placebocontrolled, double-blind study (J-BAF Study). Circ J 2009; 73: 1020-1027.
27. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
28. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al for ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
29. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, et al for Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687.
30. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995; 122: 689-700.
31. Hirao K. Does bepridil create a paradigm shift in the treatment of persistent atrial fibrillation? Circ J 2009; 73: 1008-1009.
32. Chinushi M, Restivo M, Caref EB, El-Sherif N. Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome: Tridimensional analysis of the kinetics of cardiac repolarization. Circ Res 1998; 83: 614-628.
33. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96: 4392-4399.
34. Michael G, Xiao L, Qi XY, Dobrev D, Nattel S. Remodelling of cardiac repolarization: How homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res 2009; 81: 491-499.
35. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997; 35: 13-29.
36. Nair LA, Grant AO. Emerging class III antiarrhythmic agents: Mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997; 11: 149-167.
37. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M. HERG and KvLQT1/IKs, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998; 54: 695-703.
38. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991; 83: 536-545.
39. Izumi D, Chinushi M, Iijima K, Ahara S, Komura S, Furushima H, et al. Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog. Pacing Clin Electrophysiol 2010; 33: 950-959.
40. Charlton NP, Lawrence DT, Brady WJ, Kirk MA, Holstege CP. Termination of drug-induced torsades de pointes with overdrive pacing. Am J Emerg Med 2010; 28: 95-102.
41. Tzivoni D, Keren A, Cohen AM, Loebel H, Zahavi I, Chenzbraun A, et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53: 528-530.
42. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al; for AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513.
43. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
44. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. J Am Coll Cardiol 2006; 48: 2340-2347.
45. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: A meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009; 2: 626-633.
46. Japanese Circulation Society. Guidelines for Drug Treatment of Arrhythmias (JCS 2009) http://www.j-circ.or.jp/guideline/pdf/JCS 2009_kodama_h.pdf (January 21, 2011).
47. Montefusco A, Biasco L, Blandino A, Cristoforetti Y, Scaglione M, Caponi D, et al. Left atrial volume at MRI is the main determinant of outcome after pulmonary vein isolation plus linear lesion ablation for paroxysmal-persistent atrial fibrillation. J Cardiovasc Med (Hagerstown) 2010; 11: 593-598.
48. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, et al. A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-2053.
49. Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.
50. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
51. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al; for PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778-1785.
52. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up: A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816-861.
53. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
54. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; for RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
55. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
56. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT): The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
57. Kurita T, Motoki K, Yasuoka R, Hirota T, Akaiwa Y, Kotake Y, et al. Rhythm control should be better for the management of patients with atrial fibrillation and heart failure: Rhythm control vs. rate control: Which is better in the management of atrial fibrillation? (Rhythm-Side). Circ J 2011; 75: 979-985.